{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:45:19Z","timestamp":1795085119704,"version":"4.10.2"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the histologic response rate of high-grade squamous intraepithelial lesions (HSIL) of the cervix after topical application of 5% imiquimod cream.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>In this phase II trial, women with cervical HSIL (cervical intraepithelial neoplasia [CIN] 2\u20133) were randomly assigned to 250 mg of 5% imiquimod cream applied to the cervix weekly for 12 weeks, followed by loop electrosurgical excision procedure (LEEP) without preceding treatment. The sample size was calculated based on the HSIL regression rates previously reported by Grimm et al. The primary outcome was rate of histologic regression (to CIN 1 or less) in LEEP specimens. Prespecified secondary endpoints included surgical margin status and adverse events. Outcomes were stratified by human papillomavirus type and lesion grade (CIN 2 or CIN 3). Results were reported according to per protocol (PP) and intention-to-treat (ITT) analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Ninety women were enrolled: 49 in the experimental group and 41 in the control group. In the PP population, histologic regression was observed in 23 of 38 participants (61%) in the experimental group compared with 9 of 40 (23%) in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>=.001). Surgical margins were negative for HSIL in 36 of 38 participants (95%) in the experimental group and 28 of 40 (70%) in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>=.004). In the ITT population, rates of histologic regression also were significantly higher in the experimental group. Rates of adverse events in the experimental group were 74% (28\/38) in the PP population and 78% (35\/45) in the ITT population. Adverse events were mild, with abdominal pain being the most common. Three patients in the experimental group had grade 2 adverse events, including vaginal ulcer, vaginal pruritus with local edema, and moderate pelvic pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Weekly topical treatment with imiquimod is effective in promoting regression of cervical HSIL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT03233412.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004384","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T19:37:45Z","timestamp":1620589065000},"page":"1043-1053","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":64,"title":["Topical Imiquimod for the Treatment of High-Grade Squamous Intraepithelial Lesions of the Cervix"],"prefix":"10.1097","volume":"137","author":[{"given":"Bruno O.","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falio C.","family":"Possati-Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila P.","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Schmeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme S.","family":"Accorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 H. T. G.","family":"Fregnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Antoniazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naitielle P.","family":"Pantano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara V. V.","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziela M.","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(06)68181-6","article-title":"Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis","volume":"367","author":"Kyrgiou","year":"2006","journal-title":"Lancet"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"a1284","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/01.AOG.0000435454.31850.79","article-title":"Interval from loop electrosurgical excision procedure to pregnancy and pregnancy outcomes","volume":"122","author":"Conner","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00404-013-2955-0","article-title":"Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis","volume":"289","author":"Jin","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1067\/mjd.2000.107808","article-title":"Immunomodulatory and pharmacologic properties of imiquimod","volume":"43","author":"Sauder","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/13543784.7.3.437","article-title":"Imiquimod 5% cream (Aldara)","volume":"7","author":"Slade","year":"1998","journal-title":"Expert Opin Investig Drugs"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0192-0561(98)00068-X","article-title":"Imiquimod applied topically: a novel immune response modifier and new class of drug","volume":"21","author":"Miller","year":"1999","journal-title":"Int J Immunopharmacol"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/AOG.0b013e318254f90c","article-title":"2011 colposcopic terminology of the International Federation for cervical pathology and colposcopy","volume":"120","author":"Bornstein","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e3181d9d421","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"115","author":"Schulz","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/AOG.0b013e31825bc6e8","article-title":"Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial","volume":"120","author":"Grimm","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2007.06.003","article-title":"Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study","volume":"107","author":"Mathiesen","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa072685","article-title":"Treatment of vulvar intraepithelial neoplasia with topical imiquimod","volume":"358","author":"van Seters","year":"2008","journal-title":"N Engl J Med"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00128360-200310000-00011","article-title":"Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream","volume":"7","author":"Buck","year":"2003","journal-title":"J Low Genit Tract Dis"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/ijc.30275","article-title":"Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management","volume":"139","author":"Tainio","year":"2016","journal-title":"Int J Cancer"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2015.08.018","article-title":"Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review","volume":"139","author":"de Witte","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S1470-2045(14)70456-5","article-title":"Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT(3)VIN): a multicentre, open-label, randomised, phase 2 trial","volume":"15","author":"Tristram","year":"2014","journal-title":"Lancet Oncol"},{"key":"R23-20250423","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1097\/LGT.0000000000000214","article-title":"Topical therapy with imiquimod for vaginal intraepithelial neoplasia: a case series","volume":"20","author":"Policiano","year":"2016","journal-title":"J Low Genit Tract Dis"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3332\/ecancer.2015.531","article-title":"VIN usual type-from the past to the future","volume":"9","author":"Preti","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejogrb.2017.09.020","article-title":"Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis","volume":"218","author":"Tranoulis","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/ijgc-00009577-200509000-00029","article-title":"Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?","volume":"15","author":"Haidopoulos","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12885-016-2187-3","article-title":"TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial","volume":"16","author":"Koeneman","year":"2016","journal-title":"BMC Cancer"},{"key":"R28-20250423","doi-asserted-by":"crossref","first-page":"42 e1","DOI":"10.1016\/j.ajog.2011.06.105","article-title":"Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia","volume":"206","author":"Pachman","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R29-20250423","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.tjog.2012.09.006","article-title":"Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical\/vaginal intraepithelial neoplasia","volume":"51","author":"Lin","year":"2012","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R30-20250423","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12885-017-3108-9","article-title":"Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial","volume":"17","author":"Koeneman","year":"2017","journal-title":"BMC Cancer"},{"key":"R31-20250423","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3760\/cma.j.issn.0366-6999.2009.04.002","article-title":"Predictors and clinical significance of the positive cone margin in cervical intraepithelial neoplasia III patients","volume":"122","author":"Sun","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"R32-20250423","first-page":"637","article-title":"Positive margin prevalence and risk factors with cervical specimens obtained from loop electrosurgical excision procedures and cold knife conization","volume":"10","author":"Panna","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"R33-20250423","first-page":"586","article-title":"Factors associated with cone margin involvement in CIN patients undergoing conization-equivalent electrosurgical procedure","volume":"79","author":"Costa","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R34-20250423","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17077\/2154-4751.1249","article-title":"The impact of LEEP margin status on subsequent abnormal cervical cytology","volume":"4","author":"O'Shea AS S","year":"2014","journal-title":"Proc Obstet Gynecol"},{"key":"R35-20250423","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1016\/j.crwh.2019.e00105","article-title":"Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia\u2014a case series","volume":"21","author":"Wouters","year":"2019","journal-title":"Case Rep Womens Health"},{"key":"R36-20250423","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jdcr.2019.04.015","article-title":"Imiquimod-induced effluvium after intravaginal application for treatment of cervical intraepithelial neoplasia","volume":"5","author":"Borst","year":"2019","journal-title":"JAAD Case Rep"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:04:56Z","timestamp":1745435096000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004384"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004384","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"2020-11-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}